REGN
Regeneron Pharmaceuticals Inc. Healthcare - Biotechnology Investor Relations →
Regeneron Pharmaceuticals Inc. (REGN) closed at $676.69 as of 2026-07-17, trading 12.2% below its 200-week moving average of $771.13. This places REGN in the extreme value zone. The stock moved further from the line this week, up from -13.8% last week. The 14-week RSI sits at 37, indicating neutral momentum.
Trading volume is running at 0.8x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.71 ratio) is neutral — neither side is clearly dominating.
Over the past 1793 weeks of data, REGN has crossed below its 200-week moving average 29 times. On average, these episodes lasted 24 weeks. Historically, investors who bought REGN at the start of these episodes saw an average one-year return of +19.6%.
With a market cap of $70.9 billion, REGN is a large-cap stock. The company generates a free cash flow yield of 4.6%. Return on equity stands at 14.5%. The stock trades at 2.2x book value.
Over the past 33.6 years, a hypothetical investment of $100 in REGN would have grown to $4548, compared to $3082 for the S&P 500. That represents an annualized return of 12.0% vs 10.7% for the index — confirming REGN as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 3.5% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: REGN vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After REGN Crosses Below the Line?
Across 29 historical episodes, buying REGN when it crossed below its 200-week moving average produced an average return of +14.7% after 12 months (median +9.0%), compared to +15.4% for the S&P 500 over the same periods. 67% of those episodes were profitable after one year. After 24 months, the average return was +47.8% vs +35.1% for the index.
Each line shows $100 invested at the moment REGN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices REGN would reach each dislocation threshold.
Dislocation Price Levels
Prices where REGN's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-30.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $607.10 | Unusually cheap — potential buy zone |
| Value | +1σ | $652.98 | Cheap vs. own history |
| Fair Value | +0σ | $706.36 | Historical mean behavior |
| Expensive | -1σ | $769.25 | Expensive vs. own history |
| Deep Expensive | -2σ | $844.44 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from REGN's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
REGN has crossed below its 200-week MA 29 times with an average 1-year return of +19.6% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Apr 1992 | Nov 1992 | 32 | 41.4% | -10.3% | +4605.4% |
| Dec 1992 | Jan 1993 | 4 | 17.7% | +22.9% | +5585.7% |
| Feb 1993 | Apr 1993 | 8 | 10.5% | +6.6% | +5049.3% |
| Feb 1994 | Jul 1995 | 76 | 75.5% | -49.1% | +4862.0% |
| Nov 1995 | Nov 1995 | 3 | 14.3% | +83.0% | +6516.0% |
| Jan 1997 | Sep 1997 | 38 | 39.2% | -20.1% | +6173.8% |
| Oct 1997 | Dec 1999 | 113 | 46.5% | -21.0% | +6436.8% |
| Apr 2002 | Nov 2002 | 29 | 38.8% | -65.1% | +3529.1% |
| Dec 2002 | Dec 2005 | 158 | 72.6% | -36.7% | +3221.7% |
| May 2006 | May 2006 | 2 | 2.6% | +107.4% | +5590.4% |
| Jul 2006 | Jul 2006 | 2 | 8.7% | +54.8% | +5623.8% |
| Jun 2008 | Jul 2008 | 5 | 5.0% | +10.4% | +4503.8% |
| Nov 2008 | Dec 2008 | 3 | 13.6% | +32.3% | +4790.9% |
| Jan 2009 | Jan 2009 | 1 | 6.4% | +66.8% | +4282.0% |
| Feb 2009 | Jun 2009 | 16 | 25.4% | +71.6% | +4687.9% |
| Jun 2009 | Jul 2009 | 3 | 7.5% | +26.7% | +3901.6% |
| Oct 2009 | Nov 2009 | 3 | 14.4% | +55.6% | +3778.8% |
| Nov 2009 | Nov 2009 | 1 | 1.6% | +59.4% | +3671.6% |
| Jun 2016 | Jun 2016 | 1 | 1.6% | +52.4% | +101.0% |
| Oct 2016 | Nov 2016 | 3 | 6.9% | +19.1% | +87.7% |
| Dec 2016 | Apr 2017 | 17 | 8.6% | +2.4% | +85.9% |
| Oct 2017 | Jan 2019 | 64 | 30.7% | -17.9% | +66.7% |
| Feb 2019 | Feb 2019 | 1 | 2.1% | -6.1% | +67.7% |
| Mar 2019 | Jan 2020 | 44 | 28.8% | +22.8% | +69.5% |
| Jan 2020 | Feb 2020 | 2 | 9.9% | +55.8% | +97.6% |
| Nov 2024 | Nov 2024 | 1 | 1.4% | +3.0% | -7.6% |
| Dec 2024 | Dec 2025 | 53 | 36.0% | +1.9% | -6.7% |
| Jan 2026 | Feb 2026 | 3 | 4.0% | N/A | -7.4% |
| Mar 2026 | Ongoing | 20+ | 20.9% | Ongoing | -10.8% |
| Average | 24 | — | +19.6% | — |
Frequently Asked Questions
Is REGN below its 200-week moving average?
Yes. As of 2026-07-17, Regeneron Pharmaceuticals Inc. (REGN) is trading 12.2% below its 200-week moving average of $771.13. The current price is $676.69.
What is REGN's 200-week moving average price?
Regeneron Pharmaceuticals Inc.'s 200-week moving average is $771.13 as of 2026-07-17. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when REGN drops below its 200-week moving average?
REGN has crossed below its 200-week moving average 29 times in our data. On average, buying at that moment produced a one-year return of +19.6%. These dips have historically been decent entry points. These episodes lasted 24 weeks on average.
Is REGN a good value right now?
Here's what our data says about REGN as of 2026-07-17: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 37. Free cash flow yield is 4.6%. Return on equity is 14.5%. Price-to-book is 2.2x. This is not a buy or sell recommendation — always do your own research.
How does REGN compare to the S&P 500?
Over the past 33.6 years, $100 invested in REGN would have grown to $4548, compared to $3082 for the S&P 500. That's 12.0% annualized vs 10.7% for the index. REGN has outperformed the broader market over this period.
Does REGN pay a dividend?
Yes. Regeneron Pharmaceuticals Inc. currently pays a dividend yield of 55.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-07-17